142760.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. However, the company's liquidity position is assessed as medium, with a current ratio of 2.31, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's free cash flow is negative at -11,641,754,920 KRW, which may indicate a need for external financing or a focus on long-term investments.

Profitability metrics show a return on equity of -0.4277 and a return on assets of -0.3068, both of which are negative, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are below the industry median for pharmaceutical companies, which typically have positive returns on equity and assets. The company's operating income is also negative at -6,178,131,990 KRW, further highlighting its unprofitable operations.

The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if market conditions in its primary segment or region deteriorate.

The company's growth trajectory is uncertain, with a negative operating income and a negative free cash flow. The company's revenue for the latest period is reported at 11,216,210,530 KRW, which is lower than the analyst estimate of 80,437,360,000 KRW. This discrepancy may indicate challenges in meeting market expectations or potential issues with revenue recognition.

Risk factors include a medium liquidity risk, as the company has a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential reported. However, the company's negative operating cash flow and free cash flow may necessitate future financing activities, which could lead to dilution.

Recent events include the disclosure of a negative operating income and a negative free cash flow, which may impact investor sentiment. The company has not reported any significant new product launches or strategic acquisitions in the latest period, which may affect its future growth prospects.